Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.

Abstract: An agent for prophylactic and/or therapeutic treatment of retinopathy, which comprises a hepatocyte growth factor (HGF) as an active ingredient.

Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.

Abstract: The invention relates to an ophthalmic agent comprising, as an active ingredient, a compound having a cardiotonic action including a phenyl pyridazinone derivative or salt thereof, or a hydrate thereof or solvate thereof as a typical example. Specifically, the invention relates to a preventative and/or therapeutic agent for optic nerve diseases or retinal diseases.

Abstract: An auxiliary method for an ophthalmic operation and a method for prevention of easy clotting of intraoperative bleeding, in which (2R,4R)-4-methyl-1-[N2((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid, a hydrate thereof, or pharmaceutically acceptable salts thereof is used. According to the present invention, treatment for intraoperative bleeding becomes easier, so that loads of a patient and an operator can be reduced and incidence of intraoperative iatrogenic retinal tear can be lowered.

Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.

Abstract: This invention is aimed at providing a novel medicine for oculopathy, which has as an active component thereof a 5-HT.sub.1A receptor ligand such as, for example, an alkylene dioxybenzene derivative represented by the following formula (I) ##STR1## wherein m represents an integer in the range of 2-5 and n an integer in the range of 1-3), a racemate thereof, or an acid addition salt thereof.

Abstract: A lacrimation accelerating agent containing a ligand of serotonin receptor as an active ingredient. Also provided is a method for preventive and/or therapeutic treatment of a disease caused by a deficiency of lacrimal fluid such as dry eye, which comprises the step of administering to a mammal an effective amount of a ligand of a serotonin receptor such as sarpogrelate hydrochloride.

Abstract: The present invention provides a novel drug for treating glaucoma.The present invention relates to a therapeutic agent for glaucoma and an ocular hypotensive agent, which comprise an aminoalkoxybibenzyl represented by the formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.5 alkoxy group, etc.; R.sup.2 represents a hydrogen atom, a halogen atom, etc.; R.sup.3 represents a hydrogen atom, a hydroxyl group, --O--CO--(CH.sub.2).sub.I --COOH (wherein I is an integer of 1 to 3), etc.; and R.sup.4 represents --NR.sup.5 R.sup.6 (wherein R.sup.5 and R.sup.6 independently represent a hydrogen atom or a C.sub.1 -C.sub.8 alkyl group), etc.or a salt thereof as an active ingredient.

Abstract: A method for preventing fibrin formation in anterior chamber characterized by administering argatroban into the anterior chamber is provided. A phermaceutical preparation for irrigation, eye drop, and drip infusion to effect the said method is also provided.